DOI:

Paclitaxel-eluting stent restenosis shows three-layer appearance by optical coherence tomography

Shuzou Tanimoto, MD; Jiro Aoki, MD; Patrick W. Serruys, MD, PhD; Evelyn Regar*, MD, PhD

A 73-year-old woman with hypertension, hyperlipidemia and positive familial history of coronary artery disease presented with Canadian Cardiovascular Society class III angina and underwent coronary angiography, which showed a chronic occluded right coronary artery (Panel A). The vessel was recanalized and treated with three paclitaxel-eluting stents (TAXUS®, Boston Scientific: 3.5 x 32 mm distally, 3.5 x 28 mm in the middle part, 3.5 x 12 mm proximally). Postintervention coronary angiography showed a good result (Panel B). Twelve-month follow-up angiography revealed focal in-stent restenosis (Panel C). Intracoronary optical coherence tomography (OCT: LightLabImaging™, Boston, MA, USA) pullback displayed well-expanded stents covered with a thin, homogenous, highly reflective neointimal layer (Panel D, E). In contrast, the narrowest lesion site (minimal lumen area 1.1 mm2; stent area 9.0 mm2) showed a three-layer appearance of the neointima (Panel F). The inner luminal layer appeared concentric, homogenous and signal-rich (maximal thickness 0.27 mm). A second layer consisting of a low-reflective area with poorly delineated borders followed. The third layer was in direct contact with the stent struts and revealed only minimal signal intensity. These signal-poor areas (maximal thickness 1.18 mm) might represent acellular fibrinoid deposition that has been well described in experimental studies. The patient was re-treated with repeat paclitaxel-eluting stent implantation.

OCT is an analogue of intravascular ultrasound with an ultra-high resolution (10 µm) superior to any current available imaging modalities. This imaging device may be useful in visualizing neointimal growth in drug-eluting stents and improve our understanding of its underlying physiopathology in the future.

Volume 1 Number 4
Feb 20, 2006
Volume 1 Number 4
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00601 Jun 15, 2026
Unloading the clock: when timing meets physiology in STEMI shock
Møller J and Schrage B
free

Editorial

10.4244/EIJ-D-26-00394 Jun 15, 2026
Transcatheter edge-to-edge repair for primary mitral regurgitation: what lies ahead?
Petronio A and Mazzola M
free

Original Research

10.4244/EIJ-D-25-01308 Jun 15, 2026
Temporal trends in mitral edge-to-edge repair for primary mitral regurgitation
Koell B et al

Flashlight

10.4244/EIJ-D-25-01353 Jun 15, 2026
Transcatheter approximation of papillary muscles
Tekieli L et al
open access

Editorial

10.4244/EIJ-D-26-00479 Jun 1, 2026
Valve thrombosis or valve deterioration: what truly drives the prognosis?
Waksman R and Phichaphop A
free
Trending articles
335.05

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
202.75

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
33.05

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
27.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
27.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved